• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Category: Company

SLAS 2022 – HTS Assays and Discovery Services

Wednesday, 05 January 2022 by Bellbrook Labs
SLAS 2022
BellBrook Labs will exhibit and present posters at the upcoming SLAS 2022 conference in Boston, MA. At the conference BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, targeting kinases involved in the innate immune response, navigating hit prioritization after screening using biochemical assays, assay development, lead discovery
SLAS 2022
Read more
  • Published in Company, News
No Comments

TREX1 Inhibitor Assays May Aid the Discovery Novel HIV Treatments

Monday, 17 May 2021 by Bellbrook Labs
TREX1 Inhibitor Assays
TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or
TREX1TREX1 Inhibitors
Read more
  • Published in Company, Emerging Targets
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases

Tuesday, 20 April 2021 by Bellbrook Labs
cGAS Phase II Press Release Graphic
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
cGAS InhibitorsTranscreener cGAMP cGAS Assay
Read more
  • Published in Company, News
No Comments

BellBrook Labs Receives NIH Funding for Novel Approach to Stimulating Antitumor Immunity

Tuesday, 09 March 2021 by Bellbrook Labs
TREX1 Press Release Graphic
The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway. Madison, WI – March 2021 – BellBrook Labs has been awarded a $300,000 Phase I Small
TREX1
Read more
  • Published in Company, News
No Comments

Join Us for SLAS 2021 Virtual Conference

Wednesday, 13 January 2021 by Bellbrook Labs
SLAS 2021
BellBrook Labs will be exhibiting at SLAS 2021, January 25-27. Due to the pandemic, this year’s meeting will, of course, be virtual. Although, we are sad that we won’t be able to meet with you in person this year there are still plenty of opportunities to interact. We will have a virtual booth that is
SLAS 2021
Read more
  • Published in Company, News
No Comments

SLAS 2020 – Discover HTS Assays for Drug Discovery

Tuesday, 14 January 2020 by Bellbrook Labs
SLAS 2020 Conference
  BellBrook Labs will exhibit and present posters at the upcoming SLAS 2020 conference in San Diego, CA. At the conference BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, targeting ENPP1, studying CD73, screening for kinase inhibitors, using Transcreener for a cGAS drug discovery program, and more!
SLAS 2020
Read more
  • Published in Company, News
No Comments

BellBrook Labs Recap of SLAS 2019 in Washington DC.

Tuesday, 29 January 2019 by Bellbrook Labs
SLAS 2019
BellBrook Labs will be exhibiting and have poster presentations at the upcoming SLAS conference. During the meeting, BellBrook will have information available demonstrating a variety of applications for Transcreener HTS tools. Stop by booth #1702 where you can receive your copy of “A Guide to Measuring Drug-Target Residence Times with Biochemical Assays.” We are looking forward
Read more
  • Published in Company, HTS Assays
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer

Tuesday, 22 May 2018 by Bellbrook Labs
Autoimmune Disease News
The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for autoimmune diseases and cancer by targeting
Transcreener cGAMP cGAS Assay
Read more
  • Published in Company, Emerging Targets, News
No Comments

Transcreener ADP Assay Aids in Discovery of RIPK2 Inhibitors for Autoinflammation

Wednesday, 17 January 2018 by Bellbrook Labs
When the body responds to a bacterial pathogen, fragments of bacterial peptidoglycan alert a human host to the presence of a microbial invader. A receptor named NOD2 recognizes the peptidoglycans and sounds the alarm, initiating immune responses by causing the production of pro-inflammatory cytokines via NF-κB and MAP kinase pathways 1. In this manner, NOD2
Transcreener ADP Kinase Assay
Read more
  • Published in Company, HTS Assays, News, Products, Success Stories
No Comments

Discovery on Target 2017

Tuesday, 05 September 2017 by Bellbrook Labs
  Here is what you may have missed… Exhibition Learn about our new AptaFluor SAH Methyltransferase Assay Discuss which HTS assays might be a fit for your research Discover how BellBrook Labs’ services can help accelerate your drug discovery program Presentations/Talks Targeting the cGAS-STING Pathway Using a Homogenous, HTS Compatible Transcreener® cGAS Assay Thursday, September
Read more
  • Published in Company, News
No Comments
  • 1
  • 2

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...
  • Scientist Studying ALKPK1

    The Role of ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP